Empowerment and Support for the Diabetic Patient (CHANGE-D)
Primary Purpose
Type 2 Diabetes
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Health Coaching
Sponsored by
About this trial
This is an interventional supportive care trial for Type 2 Diabetes focused on measuring Type 2 diabetes, Type II diabetes
Eligibility Criteria
Inclusion Criteria:
- Type 2 diabetes
- At least one oral anti diabetic drug
- HbA1c above 7.5% ot above 0.5% of personal target
- Preparedness for change
- Fluent Hebrew or Arabic
Exclusion Criteria:
- Type 1 diabetes
- Pregnancy or lactation
- Incompetency to sign consent
- Participation in another clinical trial
- Unstable psychotic disease
- Complex health condition
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Health coaching
Standard of Care
Arm Description
Patients receive health coaching via the phone, face to face or group support, according to patients' choice
Outcomes
Primary Outcome Measures
Clinical composite
Change from baseline in a composite endpoint of HbA1c, BMI, Blood Pressure, Lipids at 6, 12 and 18 months from randomization
Secondary Outcome Measures
Change in Self Treatment Score
Change from baseline in Self treatment diabetes questionnaire score at 6, 12 and 18 months from randomization
Change in Self Efficacy Score
Change from baseline in Self Efficacy questionnaire score at 6, 12 and 18 months from randomization
Full Information
NCT ID
NCT02179385
First Posted
June 25, 2014
Last Updated
August 4, 2015
Sponsor
Clalit Health Services
Collaborators
Merck Sharp & Dohme LLC
1. Study Identification
Unique Protocol Identification Number
NCT02179385
Brief Title
Empowerment and Support for the Diabetic Patient
Acronym
CHANGE-D
Official Title
Coaching for Health to Achieve New Goals in Empowerment for Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
August 2015
Overall Recruitment Status
Unknown status
Study Start Date
June 2014 (undefined)
Primary Completion Date
June 2016 (Anticipated)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Clalit Health Services
Collaborators
Merck Sharp & Dohme LLC
4. Oversight
5. Study Description
Brief Summary
CHANGE-D objectives are to evaluate to what extent personal coaching for healthy lifestyle and treatment adherence improves clinical outcomes among uncontrolled diabetic patients.
Evaluate to what extent personal coaching for healthy lifestyle and treatment adherence improves self treatment among uncontrolled diabetic patients.
Detailed Description
Research Group 300 type 2 diabetics: 150 from Jewish sector and 150 from Arab sector will be recruited from 7-10 clinics in each district: North District and Haifa District A personal coaching intervention will be tailored from the offered tools: Face to face, group, telephone Participants will be monitored for clinical and self treatments outcomes Comparison Group 300 patients with similar characteristics to the research group will receive Clalit's standard of care Participants will be monitored for clinical and self treatments outcomes like the research group
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Type 2 diabetes, Type II diabetes
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
300 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Health coaching
Arm Type
Experimental
Arm Description
Patients receive health coaching via the phone, face to face or group support, according to patients' choice
Arm Title
Standard of Care
Arm Type
Placebo Comparator
Intervention Type
Behavioral
Intervention Name(s)
Health Coaching
Primary Outcome Measure Information:
Title
Clinical composite
Description
Change from baseline in a composite endpoint of HbA1c, BMI, Blood Pressure, Lipids at 6, 12 and 18 months from randomization
Time Frame
0, 6, 12, 18 months from randomization
Secondary Outcome Measure Information:
Title
Change in Self Treatment Score
Description
Change from baseline in Self treatment diabetes questionnaire score at 6, 12 and 18 months from randomization
Time Frame
0, 6, 12, 18 months from randomization
Title
Change in Self Efficacy Score
Description
Change from baseline in Self Efficacy questionnaire score at 6, 12 and 18 months from randomization
Time Frame
0, 6, 12, 18 months from randomization
Other Pre-specified Outcome Measures:
Title
Change in Quality of life score
Description
Change from baseline in Diabetes Quality of Life questionnaire score at 12 months from randomization
Time Frame
0, 12 months from randomization
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type 2 diabetes
At least one oral anti diabetic drug
HbA1c above 7.5% ot above 0.5% of personal target
Preparedness for change
Fluent Hebrew or Arabic
Exclusion Criteria:
Type 1 diabetes
Pregnancy or lactation
Incompetency to sign consent
Participation in another clinical trial
Unstable psychotic disease
Complex health condition
12. IPD Sharing Statement
Learn more about this trial
Empowerment and Support for the Diabetic Patient
We'll reach out to this number within 24 hrs